Seattle Genetics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

01.08.14	ALXA Working Its Way, CERS Awaits FDA Decision, XNCR, SGEN Look Ahead To Results (RTTNews)
31.07.14	Seattle Genetics Q2 Loss Widens (RTTNews)
31.05.14	Seattle Genetics Reports Data From Collaborator ADC Programs - Quick Facts (RTTNews)
01.05.14	Seattle Genetics Posts Loss (RTTNews)
09.04.14	ALKS, SGEN To Watch Out, Capstone Dons New Hat, PRTA Pockets $15 Mln (RTTNews)
11.02.14	Seattle Genetics Q4 Loss Widens - Quick Facts (RTTNews)
17.01.14	Seattle Genetics: Takeda Gets Approval For Adcetris In Japan (RTTNews)
07.12.13	Seattle Genetics Presents Interim Phase1 Clinical Data From SGN-CD19A (RTTNews)
06.11.13	MYGN, SGEN Boost Outlook, AMRI On A High, ENDP Opens Wallet, IMGN Slammed (RTTNews)
05.11.13	Seattle Genetics Q3 Loss Widens - Quick Facts (RTTNews)
22.10.13	Oxygen Bio Breathes Anew, KERX Gets FDA Date, Rockwell Continues To Rock (RTTNews)
21.10.13	Seattle Genetics Begins Phase 1 Trial Of ADC Candidate SGN-LIV1A (RTTNews)
21.10.13	Sales Strategies, Upcoming Financial Results Schedules, Clinical Study Updates, and FDA Agreements - Research Report on Arena, Seattle Genetics, Halozyme, Insmed, and Omeros (PR Newswire)
15.10.13	Under AAAResearchReports.com Microscope: Amarin Corp. PLC, Elan Corp. PLC, Seattle Genetics Inc., and Cubist Pharma Inc. (PR Newswire)
11.10.13	Seattle Genetics Reports ADCETRIS Data In Frontline Setting On Hodgkin Lymphoma (RTTNews)
07.10.13	Partnerships, Product Recall, New Contracts, Promotions, and Stock Movement - Research Report on Valeant, CareFusion, Envision Healthcare, Seattle Genetics, and Osiris (PR Newswire)
03.10.13	Critical Alerts For Exxon Mobil, Citigroup, Dollar Tree, Oracle, and Seattle Genetics Released By InvestorsObserver (PR Newswire)
16.09.13	Pre-Market Analysis: Amarin Corp. PLC, Elan Corp. PLC, Cubist Pharmaceuticals Inc., and Seattle Genetics Inc. (PR Newswire)
05.09.13	Critical Alerts For Coca Cola, Royal Gold, Rackspace Hosting, Herbalife, and Seattle Genetics Released By InvestorsObserver (PR Newswire)
29.08.13	Clinical Trials, Pipeline Developments, Financial Results, and New Appointments - Research Report on Amarin, Immunomedics, Seattle Genetics, Repros Therapeutics, and LifePoint (PR Newswire)
15.08.13	Seattle Genetics Initiates Phase 2 Trial Of Adcetris In Combination With RCHOP (RTTNews)
08.08.13	Today's Research: Elan Corp. PLC, Amarin Corp. PLC, Seattle Genetics Inc., and Cubist Pharmaceuticals Inc. (PR Newswire)
05.08.13	Critical Alerts For Coca Cola, Genuine Parts, Boyd Gaming, Chesapeake Energy, and Seattle Genetics Released By InvestorsObserver (PR Newswire)
05.08.13	Accretive Collaborations, Strengthened Management, and Earnings Release Schedules - Research Report on Seattle Genetics, Santarus, BioCryst, NPS, and PDL BioPharma (PR Newswire)
31.07.13	Seattle Genetics Q2 Loss Narrows - Quick Facts (RTTNews)
09.02.10	Seattle Genetics Reports Fourth Quarter and Year 2009 Financial Results and Provides 2010 Financial Outlook (Businesswire)
05.01.10	Seattle Genetics to Present at the J.P. Morgan Healthcare Conference (Businesswire)
01.12.09	Seattle Genetics to Present Brentuximab Vedotin and Dacetuzumab Data at the 51st American Society of Hematology Annual Meeting and Exposition (Businesswire)
01.06.09	Seattle Genetics Reports Data from a Weekly Dosing Phase I Clinical Trial of SGN-35 in Lymphoma (Businesswire)
19.02.09	Seattle Genetics Initiates Pivotal Trial of SGN-35 for Hodgkin Lymphoma (Businesswire)
05.02.09	Seattle Genetics Reports Fourth Quarter and Year 2008 Financial Results and Provides 2009 Financial Outlook (Businesswire)
02.06.08	Seattle Genetics Announces Initiation of SGN-40 Phase Ib Clinical Trial in Combination With Velcade for Multiple Myeloma (Businesswire)
16.05.08	Seattle Genetics Announces Upcoming SGN-35 Presentation at the American Society of Clinical Oncology Annual Meeting (Businesswire)
24.04.08	Seattle Genetics Reports First Quarter 2008 Financial Results (Businesswire)
10.12.07	Seattle Genetics Reports Multiple Complete Remissions With SGN-33 in Acute Myeloid Leukemia at ASH (Businesswire)
18.07.06	Seattle Genetics to Host Conference Call and Webcast Discussion of Second Quarter 2006 Results on July 25, 2006 (Businesswire)
16.05.05	Seattle Genetics Provides Update on SGN-30 and SGN-40 Clinical Program (Businesswire)
08.02.05	Seattle Genetics Reports Fourth Quarter and Year 2004 Results (Businesswire)
27.01.05	Seattle Genetics to Host Conference Call and Webcast Discussion of 200 (Businesswire)
19.01.05	Seattle Genetics Receives Key U.S. Patents for SGN-40 Program (Businesswire)
06.01.05	Seattle Genetics to Present at JPMorgan Healthcare Conference (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Nestle	85.10	3.35 %	K V
Novartis	98.15	1.54 %	K V
Roche Hldg G	298.40	1.05 %	K V
Givaudan	3’927.00	1.00 %	K V
Sika	237.80	0.85 %	K V
CieFinRichemont	180.35	0.14 %	K V
Swiss Re	138.30	-0.04 %	K V
Lonza Grp	583.60	-0.10 %	K V
ABB	52.26	-0.19 %	K V
Holcim	94.36	-0.49 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Seattle Genetics Inc.

Aktien Top/Flop

Meistgelesene Nachrichten